Description: Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Home Page: citiuspharma.com
11 Commerce Drive
Cranford,
NJ
07016
United States
Phone:
908 967 6677
Officers
| Name | Title |
|---|---|
| Mr. Leonard L. Mazur | Co-Founder, CEO, Chairman & Secretary |
| Mr. Myron Z. Holubiak | Co-Founder & Executive Vice Chairman |
| Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer |
| Mr. Jaime Bartushak | Chief Business Officer, CFO & Chief Accounting Officer |
| Mr. Gary F. Talarico | Executive Vice President of Operations |
| Ms. Ilanit Allen | Vice President of Investor Relations & Corporate Communications |
| Dr. Alan Lader Ph.D. | Senior VP and Head of Clinical Operations & Quality Assurance |
| Mr. Dhananjay G. Wadekar | Senior Vice President of Business Strategy |
| Mr. Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing & Controls |
| Mr. Nikolas Burlew | Executive Vice President of Quality Assurance |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 9.2851 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3141 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 22 |